Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
HOOKIPA Pharma (NASDAQ:HOOK) has received mixed analyst ratings over the past quarter, with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target is $5.38, down 17.23% from the prior average. The company has shown impressive financial performance with significant revenue growth, strong net margins, and effective debt management.
May 21, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HOOKIPA Pharma has received mixed analyst ratings with an average 12-month price target of $5.38, indicating a 17.23% decline from the prior average. The company has shown strong financial performance with significant revenue growth, strong net margins, and effective debt management.
The mixed analyst ratings suggest a neutral short-term impact on the stock price. However, the company's strong financial performance, including significant revenue growth and effective debt management, provides a positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100